Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
What It Is
Tirzepatide is a first-in-class dual incretin agonist that activates both the GIP and GLP-1 receptors. FDA-approved under the brand names Mounjaro (diabetes) and Zepbound (weight management), it has demonstrated significant weight loss and glycemic control in clinical trials. In 2026, tirzepatide received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stages F2 or F3 — becoming the second FDA-approved pharmacotherapy for MASH after resmetirom (Rezdiffra). The SYNERGY-NASH Phase 2 trial showed 51.8%, 62.8%, and 73.3% of participants on 5 mg, 10 mg, and 15 mg doses achieved MASH resolution with no worsening of fibrosis at 52 weeks, compared to 13.2% on placebo. Additionally, 59.1%, 53.3%, and 54.2% of participants across doses achieved 1-stage or greater fibrosis improvement without worsening of MASH versus 32.8% on placebo. The FDA granted breakthrough therapy designation for this indication. In a landmark head-to-head trial published in the New England Journal of Medicine (2025), tirzepatide was shown to be superior to semaglutide with respect to body weight reduction: the mean percent change in weight at week 72 was −20.2% with tirzepatide versus −13.7% with semaglutide, with tirzepatide also producing greater waist circumference reductions. The SURMOUNT trial series showed average weight loss of 20–25% of body weight in some cohorts. In the Phase 3 SURMOUNT-OSA trial, tirzepatide demonstrated a reduction of 25.3 to 29.3 events per hour in apnea-hypopnea index versus approximately 5 with placebo, alongside 17–20% body weight reduction — establishing a potential role in treating obesity-related obstructive sleep apnea. Tirzepatide is also in clinical trials for autoimmune conditions in adults with obesity — notably, Phase 3 trials combining tirzepatide with ixekizumab (Taltz) for plaque psoriasis and psoriatic arthritis in patients with obesity are expected to complete in the first half of 2026. Mounjaro is under FDA review for a new indication to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes, with a decision expected in early-to-mid 2026. Tirzepatide monotherapy is also in clinical trials for type 1 diabetes (estimated completion 2027). The Phase 3 SUMMIT trial demonstrated that tirzepatide reduced the composite risk of cardiovascular death or worsening heart failure by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity over a median follow-up of approximately 2 years. Participants showed significant improvements in physical function, exercise tolerance, weight loss, and reduced systemic inflammation. While tirzepatide is not yet FDA-approved for HFpEF, these results position it as a potential first incretin therapy for obesity-related heart failure, with regulatory submission anticipated. A May 2026 meta-analysis of over 90,000 participants across multiple GLP-1 RA clinical trials confirmed that the GLP-1 receptor agonist class — including both semaglutide and tirzepatide — significantly reduces cardiovascular events including heart attacks, strokes, and heart failure hospitalization, further reinforcing the cardiometabolic benefits of incretin-based therapies.
Regulatory Status
FDA-approved as Mounjaro for type 2 diabetes (May 2022), as Zepbound for chronic weight management (November 2023), and for MASH with moderate-to-advanced fibrosis (early 2026). 73.3% of patients taking 15 mg achieved MASH resolution at 52 weeks in SYNERGY-NASH. SUMMIT trial for HFpEF with obesity submission anticipated.
Effective: 2026
View FDA SourceEvidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 3 (SURMOUNT) | Dual GIP/GLP-1 agonist | Average weight loss of 20-25% of body weight | Source |
| Phase 3 (SURMOUNT-5) | Tirzepatide vs semaglutide head-to-head | Statistically superior weight loss vs semaglutide 2.4mg | Source |
| Phase 3 (SURMOUNT-OSA) | Tirzepatide in obesity-related OSA | 25.3–29.3 AHI reduction vs ~5 placebo; 17–20% weight loss | Source |
| Phase 3 (NEJM 2025) | Tirzepatide vs semaglutide head-to-head, 72 weeks | −20.2% weight loss (tirzepatide) vs −13.7% (semaglutide); superior waist circumference reduction | Source |
| Phase 2 (SYNERGY-NASH) | Tirzepatide 5/10/15 mg vs placebo in MASH with fibrosis F2-F3, 52 weeks | 73.3% MASH resolution at 15 mg vs 13.2% placebo; 54.2% achieved ≥1-stage fibrosis improvement without worsening of MASH; led to FDA breakthrough therapy designation and 2026 MASH approval | Source |
| Phase 3 (SUMMIT) | Tirzepatide in HFpEF with obesity (n=731), median ~2 years follow-up | 38% reduction in cardiovascular death or worsening heart failure; improved exercise tolerance and physical function; significant weight loss and reduced inflammation | Source |
Commonly Discussed Benefits
Safety & Cautions
- FDA-approved prescription medication requiring medical supervision
- Common side effects include nausea, diarrhea, and decreased appetite
- Contraindicated in patients with personal/family history of medullary thyroid carcinoma
- Not for use with other GLP-1 receptor agonists
- On May 1, 2026, the FDA proposed excluding tirzepatide (along with semaglutide and liraglutide) from the 503B Bulks List. Public comment period closes June 29, 2026.
Comparisons
See how Tirzepatide compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Jastreboff AM. et al. — Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022 PubMed
- [2] Genetic predictors of GLP1 receptor agonist weight loss and side effects — Nature 2026 PubMed
- [3] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — NEJM 2025 PubMed
- [4] FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — FDA. May 2026 PubMed
- [5] Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis — NEJM 2024 PubMed
- [6] Eli Lilly — SYNERGY-NASH Phase 2 results: MASH resolution and fibrosis improvement PubMed
- [7] SUMMIT Trial -- Effects of tirzepatide on heart failure with preserved ejection fraction and obesity. Nature Medicine, 2024 PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Retatrutide
High EvidenceAn investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.
Cagrilintide
High EvidenceA long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.
Survodutide
Medium EvidenceA dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026.
Mazdutide
High EvidenceThe first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide.
Maridebart Cafraglutide (MariTide)
Medium EvidenceAmgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1.
Ribupatide
Medium EvidenceA once-weekly injectable GLP-1/GIP dual receptor agonist in Phase 3 trials for obesity, with an oral formulation in development and backed by a record-setting $625M biotech IPO.
MariTide
High EvidenceA bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes.
NA-931 (Bioglutide)
Medium EvidenceThe first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation.
CagriSema
High EvidenceA fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways.
UBT251
Medium EvidenceA GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space.